ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.

Phase 3 Completed 315 enrolled Assistance Publique - Hôpitaux de Paris Ministry of Health, France · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration of TXA to TER to placebo in patients with mild to severe hemoptysis.

Timeline

Start: 2022-03-27
Primary completion: 2025-12-28
Completion: 2026-03-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Terlipressin	Peptide	1 mg	Inhaled
Subject	Tranexamic Acid	Small molecule	500 mg	Inhaled

Indications

No indication recorded.